PFE: מכפיל מחיר להכנסות Pfizer Corporation

Pfizer Inc. (PFE) minimizes risks through a broad portfolio of vaccines and oncology drugs. The company's P/S ratio reflects valuation dynamics relative to sales, where the 2.60 mark characterizes this parameter. The holding is implementing "green chemistry" to reduce production toxicity. Business stability relies on patent protection and government healthcare spending.

To protect capital from market volatility, it is essential for investors to correlate the market value of Pfizer Inc. (PFE) with its actual earnings. The company's global distribution scale and government contracts ensure revenue stability, making the price-to-sales ratio a key valuation tool: this metric indicates how many dollars of market capitalization are attributed to each unit of sales, helping to determine the asset's degree of overvaluation and avoid excessive portfolio risks.